Large retrospective studies have demonstrated that for NPC patients, anti-EGFR therapy has similar benefits as chemotherapy but with less severe toxicity, such as hematologic toxicities and gastrointestinal reactions (9). Here, EGFR is linked to nasopharyngeal carcinoma.